Impact of virologic breakthrough and HBIG regimen on hepatitis b recurrence after liver transplantation

American Journal of Transplantation

Volumn 10, Issue 8, 2010, Pages 1823-1833

  Degertekin, B ^a   Han, Steven Huy B ^b   Keeffe, E B ^c   Schiff, E R ^d   Luketic, V A ^e   Brown Jr , R S ^f   Emre, S ^g   Soldevila Pico, C ^h   Reddy, K R ⁱ   Ishitani, M B ^j   Tran, T T ^k   Pruett, T L ^l   Lok, A S F ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f New York Presbyterian Hospital Columbia University Medical Center   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF FLORIDA   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j MAYO CLINIC   (United States)

^k CEDARS SINAI MEDICAL CENTER   (United States)

^l UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

Adefovir; antiviral resistance; HBV DNA; hepatitis B e antigen; lamivudine

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; FEMALE; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS MUTATION;

ADOLESCENT; ADULT; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE;

EID: 77954944543     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03046.x     Document Type: Article

References (29)

1. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993 329:1842 1847.
2. Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998 27 : 213 222.
3. Dan YY, Wai CT, Yeoh KG, Lim SG. Prophylactic strategies for hepatitis B patients undergoing liver transplant: A cost-effectiveness analysis. Liver Transpl 2006 12 : 736 746.
4. Marzano A, Gaia S, Ghisetti V et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005 11 : 402 409.
5. McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996 61 : 1358 1364.
6. Dickson RC, Terrault NA, Ishitani M et al. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl 2006 12 : 124 133.
7. Gane EJ, Angus PW, Strasser S et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007 132 : 931 937.
8. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000 6 : 429 433.
9. Zheng S, Chen Y, Liang T et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006 12 : 253 258.
10. Mutimer D, Pillay D, Dragon E et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999 30 : 715 721.
11. Mutimer D, Feraz-Neto BH, Harrison R et al. Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: Rapid resolution during treatment with adefovir. Gut 2001 49 : 860 863.
12. Osborn MK, Han SH, Regev A et al. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol 2007 5 : 1454 1461.
13. Fontana RJ, Hann HW, Perrillo RP et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002 123 : 719 727.
14. Kamar N, Milioto O, Alric L et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008 86 : 611 614.
15. Lo CM, Liu CL, Lau GK, Chan SC, Ng IO, Fan ST. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl 2005 11 : 807 813.
16. Schiff E, Lai CL, Hadziyannis S et al. Adefovir dipivoxil for wait-listed and postliver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. Liver Transpl 2007 13 : 349 360.
17. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as postliver transplantation hepatitis B prophylaxis. Hepatology 2008 48 : 1460 1466.
18. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: Long-term results. Am J Transplant 2003 3 : 999 1002.
19. Han SH, Martin P, Edelstein M et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003 9 : 182 187.
20. Han SH, Ofman J, Holt C et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000 6 : 741 748.
21. Wong SN, Reddy KR, Keeffe EB et al. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl 2007 13 : 334 342.
22. Liu Y, Hussain M, Wong S, Fung SK, Yim HJ, Lok AS. A genotype-independent real-time PCR assay for quantification of hepatitis B virus DNA. J Clin Microbiol 2007 45 : 553 558.
23. Degertekin B, Hussain M, Tan J, Oberhelman K, Lok AS. Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance. J Hepatol 2009 50 : 42 48.
24. Hussain M, Fung S, Libbrecht E et al. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J Clin Microbiol 2006 44 : 1094 1097.
25. Naoumov NV, Lopes AR, Burra P et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001 34 : 888 894.
26. Perrillo RP, Wright T, Rakela J et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001 33 : 424 432.
27. Lok AS. Prevention of recurrent hepatitis B postliver transplantation. Liver Transpl. 2002 8 (10 Suppl 1 S67 S73.
28. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004 24 (Suppl 1 55 62.
29. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007 14 (Suppl 1 37 44.